Exploring the Landscape of Biomarkers in Spinal Cord Injury

Area of Science:

• Neuroscience
• Biomarker Discovery
• Spinal Cord Injury Research

Background:

• Significant progress in spinal cord injury (SCI) research necessitates improved methods for predicting recovery and identifying treatment responders.
• Current neurological assessment tools like the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) have limitations.
• Accurate and sensitive biomarkers are essential for advancing SCI diagnosis, prognosis, and therapeutic development.

Purpose of the Study:

• To summarize key insights from a 2024 Spinal Cord Outcome Partnership Endeavour (SCOPE) precourse on the utility and application of biomarkers in SCI.
• To discuss the scope and value of diverse biomarker types in SCI clinical trials and practice.
• To highlight the potential of reliable biomarkers in accelerating SCI research and enabling precision medicine.

Main Methods:

• A summary of discussions from an international panel at the American Spinal Injuries Association (ASIA) meeting precourse.
• Review of the current landscape and future directions for biomarker application in SCI.
• Categorization of biomarkers from molecular to systems levels.

Main Results:

• Biomarkers are crucial for predicting recovery and guiding intervention in spinal cord injury.
• Various biomarker types (molecular, cellular, neural circuits, systems, movement) offer valuable insights.
• No FDA-qualified SCI biomarkers currently exist, but their development is a priority.

Conclusions:

• Reliable biomarkers are vital for accelerating SCI research and enabling more precise treatment strategies.
• The application of biomarkers differs between research settings and clinical practice.
• Continued development and validation of SCI biomarkers hold significant promise for patient outcomes.